“
TL;DR
The authors acknowledge that translation of nanodrugs to clinical practice remains limited by synthetic complexity, safety and toxicity concerns, optimization of physicochemical properties, cost, and the need for specialized training.
Frontiers in Cellular Neuroscience · 6 authors, 7 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The authors acknowledge that translation of nanodrugs to clinical practice remains limited by synthetic complexity, safety and toxicity concerns, optimization of physicochemical properties, cost, and the need for specialized training.
The authors acknowledge that translation of nanodrugs to clinical practice remains limited by synthetic complexity, safety and toxicity concerns, optimization of physicochemical properties, cost, and the need for specialized training.